You cannot apply for this job anymore (deadline was 5 Mar 2018).
Browse the current job offers or choose an item in the top navigation above.
Your challenge
As a postdoc your main tasks and responsibilities are:
We are looking for a highly motivated and enthusiastic post-doctoral researcher with:
Salary Scale 10: 2659 tot 4216 euro gross when employed full-time (depending on qualifications and experience).
Apart from an excellent salary we also offfer an 8.3% year-end bonus and 8% holiday pay. For more information see our working conditions on the website .
For Dutch citizens it is mandatory to provide a VOG (Verklaring Omtrent Gedrag).
VU University Medical Center was founded on 1 January 2001. It was created by the integration of the VU hospital, which opened in 1966, and the Vrije Universiteit Amsterdam's Faculty of Medicine, which was founded in 1950. The history of medical science at VU Amsterdam stretches back to the beginning of the last century. The motto adopted by the VU hospital was 'Medicina Miseriacordiae Ministra' (medicine is the servant of mercy). This motto characterizes the Christian tradition from which the VU hospital sprang. Its priorities are human dignity and respectful treatment.
Within Cancer Cancer Amsterdam the Molecular Pathology research group is one of the world’s leading translational research groups in the area of human papillomavirus (HPV) induced carcinogenesis (www.hpvstudies.nl). Our research aims to unravel the molecular pathogenesis of HPV-induced cancer using cutting edge technologies. The gained molecular knowledge is translated into clinically applicable biomarker tests for (early) cancer detection and improving outcomes.
For a project recently granted by the Dutch Cancer Society we are looking for a talented and enthousiastic postdoc. The project is dedicated to obtain important basic insights into the molecular origin of anchorage-independent growth, which particularly reflects the transition of precancerous lesions to invasive cancer. By functional genomics miRNAs and their mRNA targets involved in acquisition of anchorage-independent growth will be characterized using a unique in vitro model system of HPV-containing keratinocytes. For genome-wide miRNA mimic screens we have developed and validated a novel methodology on ultra-low attachment surface culture plates. The biologically relevant mRNA targets will be identified by a CRISPR-Cas9 knock-out screen. Upon data analysis supported by the Epidemiology and Biostatistics department, functional validation experiments will be conducted. The miRNAs and mRNA targets regulating anchorage independent growth are expected to provide diagnostic biomarkers for early cancer detection and treatment.
We like to make it easy for you, sign in for these and other useful features: